帕金森病的药物坚持:纵向变化和抑郁症状的影响
Konstantin G Heimrich1,2, Aline Schönenberg3, Gabriele Helga Franke4
1Department of Geriatrics, Jena University Hospital, Jena, Germany.
Patient preference and adherence
|September 15, 2025
概括
帕金森病 (PD) 的药物坚持随着时间的推移而变化. 提高坚持要求解决遗忘和抑郁症状,而不仅仅是知识差距.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 帕金森病 (PD) 的管理涉及复杂的药物治疗方案.
- 患者对药物的坚持对于长期治疗成功至关重要.
- 了解PD的纵向粘附模式对于有效的干预措施至关重要.
研究的目的:
- 为了研究帕金森病患者随着时间的推移有意和无意的不坚持的演变.
- 为了确定影响药物坚持的纵向变化的帕金森病相关因素.
- 为制定有针对性的干预措施提供信息,以改善PD的坚持.
主要方法:
- 一组91名帕金森病患者在出院后被跟踪了6个月.
- 使用Stendal药物坚持评分 (SAMS) 和其子评分 (遗忘,知识,修改) 来评估药物坚持.
- 统计分析,包括概括估计方程,用于分析纵向变化和影响因素.
主要成果:
- 修改和知识的坚持得分在六个月的随访期间有所改善.
- 遗忘,这是无意不遵守的关键方面,没有显著变化.
- 药物治疗方案的修改与抑郁症状有显著的关联.
结论:
- 帕金森病的药物坚持是一个由各种因素影响的动态过程.
- 虽然教育干预可以提高知识,但解决抑郁症状对于提高整体坚持至关重要.
- 未来的研究应该专注于有针对性的策略,以支持PD患者的持续坚持.
相关概念视频
Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Drug Dosing: Geriatric Patients
228
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
228
Antidepressant Drugs: MAOIs and Other Agents
828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476


